A recent clinical trial demonstrated that breast cancer patients with germline mutations in BRCA1 or BRCA2 benefit from Poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitor treatment [9]. This evidence concerns the gene BRCA2 and breast carcinoma.